CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

近年来，减肥药物市场一度成为投资者关注的焦点，随着Novo Nordisk的Wegovy和Eli ...

根据Bernstein的分析，Eli Lilly（LLY）在选举后的下跌可能被夸大了，因为当选总统特朗普的一位亲密盟友似乎支持减肥药物。这家制药公司的股票自选举日以来已下跌超过6%，这也导致了整个行业许多公司股价下跌的部分因素。特朗普宣布将Robert F. Kennedy Jr.任命为领导卫生与公共服务部的候选人后，Eli ...

In a recent head-to-head study involving Novo Nordisk 's Wegovy, Zepbound came out on top, resulting in average weight loss ...

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

药企正扩展其潜力 ...

A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.